Biotech Values

[genisi]

VRUS R7128 preclinical tox

While information is incomplete, (for example was the tox related to specific metabolite which is metabolized more extensively in monkeys), I think that since the monkey studies did not prevent the start of phase 2b trials designed with up to 1,000mg BID, I am cautiously optimistic about this.
On NOAEL, please see my reply to dewo.